Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Serious outcomes
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 melatonin studies
00.250.50.7511.251.51.752+Alizadeh (SB RCT)73%0.27 [0.07-1.05]no recov.2/149/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.07-1.05]2/149/1773% improvementRamlall87%0.13 [0.08-0.22]death196 (n)752 (n)Improvement, RR [CI]TreatmentControlDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Hosseini48%0.52 [0.36-0.77]recov. time20 (n)20 (n)Farnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Sánchez-González54%0.46 [0.28-0.71]death24/22453/224Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Tau​2 = 0.35; I​2 = 74.5%Late treatment66%0.34 [0.18-0.65]27/52261/1,07466% improvementJehi58%0.42 [0.26-0.68]cases16/529802/11,143Improvement, RR [CI]TreatmentControlZhou (PSM)21%0.79 [0.65-0.94]casesTau​2 = 0.17; I​2 = 83.5%PrEP40%0.60 [0.33-1.11]16/529802/11,14340% improvementAll studies60%0.40 [0.25-0.65]45/1,065872/12,23460% improvement9 melatonin COVID-19 studiesc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.34; I​2 = 85.4%; Z = 3.68Effect extraction pre-specifiedFavors melatoninFavors control 00.250.50.7511.251.51.752+Alizadeh (SB RCT)73%0.27 [0.07-1.05]no recov.2/149/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.07-1.05]2/149/1773% improvementRamlall87%0.13 [0.08-0.22]death196 (n)752 (n)Improvement, RR [CI]TreatmentControlDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Hosseini48%0.52 [0.36-0.77]recov. time20 (n)20 (n)Farnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Tau​2 = 0.64; I​2 = 78.1%Late treatment69%0.31 [0.12-0.79]3/2988/85069% improvementJehi58%0.42 [0.26-0.68]cases16/529802/11,143Improvement, RR [CI]TreatmentControlZhou (PSM)21%0.79 [0.65-0.94]casesTau​2 = 0.17; I​2 = 83.5%PrEP40%0.60 [0.33-1.11]16/529802/11,14340% improvementAll studies61%0.39 [0.22-0.69]21/841819/12,01061% improvement8 melatonin COVID-19 studies after exclusionsc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.42; I​2 = 86.5%; Z = 3.22Effect extraction pre-specifiedFavors melatoninFavors control 00.250.50.7511.251.51.752+Ramlall87%0.13 [0.08-0.22]196 (n)752 (n)Improvement, RR [CI]TreatmentControlSánchez-González54%0.46 [0.28-0.71]24/22453/224Mousavi (RCT)67%0.33 [0.04-3.09]1/483/48Tau​2 = 0.61; I​2 = 84.1%Late treatment74%0.26 [0.09-0.74]25/46856/1,02474% improvementAll studies74%0.26 [0.09-0.74]25/46856/1,02474% improvement3 melatonin COVID-19 mortality resultsc19melatonin.com Sep 24, 2021Tau​2 = 0.61; I​2 = 84.1%; Z = 2.53Favors melatoninFavors control 00.250.50.7511.251.51.752+Darban (RCT)6%0.94 [0.84-1.06]10 (n)10 (n)CT​1Improvement, RR [CI]TreatmentControlFarnoosh (DB RCT)81%0.19 [0.01-3.65]0/242/20Mousavi (RCT)40%0.60 [0.24-1.52]6/4810/48Tau​2 = 0.00; I​2 = 0.6%Late treatment7%0.93 [0.81-1.06]6/8212/787% improvementAll studies7%0.93 [0.81-1.06]6/8212/787% improvement3 melatonin COVID-19 ICU resultsc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.6%; Z = 1.09Favors melatoninFavors control 00.250.50.7511.251.51.752+Ramlall87%0.13 [0.08-0.22]death196 (n)752 (n)Improvement, RR [CI]TreatmentControlDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Farnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Sánchez-González54%0.46 [0.28-0.71]death24/22453/224Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Tau​2 = 0.49; I​2 = 71.1%Late treatment71%0.29 [0.13-0.68]27/50261/1,05471% improvementAll studies71%0.29 [0.13-0.68]27/50261/1,05471% improvement5 melatonin COVID-19 serious outcomesc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.49; I​2 = 71.1%; Z = 2.85Effect extraction pre-specifiedFavors melatoninFavors control 00.250.50.7511.251.51.752+Jehi58%0.42 [0.26-0.68]16/529802/11,143Improvement, RR [CI]TreatmentControlZhou (PSM)21%0.79 [0.65-0.94]Tau​2 = 0.17; I​2 = 83.5%PrEP40%0.60 [0.33-1.11]16/529802/11,14340% improvementAll studies40%0.60 [0.33-1.11]16/529802/11,14340% improvement2 melatonin COVID-19 case resultsc19melatonin.com Sep 24, 2021Tau​2 = 0.17; I​2 = 83.5%; Z = 1.62Favors melatoninFavors control 00.250.50.7511.251.51.752+Alizadeh (SB RCT)73%0.27 [0.07-1.05]no recov.2/149/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.07-1.05]2/149/1773% improvementDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Improvement, RR [CI]TreatmentControlFarnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Tau​2 = 0.00; I​2 = 0.0%Late treatment55%0.45 [0.14-1.46]3/828/7855% improvementAll studies64%0.36 [0.15-0.88]5/9617/9564% improvement4 melatonin COVID-19 Randomized Controlled Trialsc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.24Effect extraction pre-specifiedFavors melatoninFavors control 00.250.50.7511.251.51.752+Mousavi (RCT)67%0.33 [0.04-3.09]1/483/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.04-3.09]1/483/4867% improvementAll studies67%0.33 [0.04-3.09]1/483/4867% improvement1 melatonin COVID-19 RCT mortality resultc19melatonin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.97Favors melatoninFavors control 00.250.50.7511.251.51.752+Alizadeh (SB RCT)73%0.27 [0.07-1.05]no recov.2/149/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.07-1.05]2/149/1773% improvementDarban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Improvement, RR [CI]TreatmentControlHosseini48%0.52 [0.36-0.77]recov. time20 (n)20 (n)Farnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Sánchez-González54%0.46 [0.28-0.71]death24/22453/224Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Tau​2 = 0.00; I​2 = 0.0%Late treatment51%0.49 [0.37-0.65]27/32661/32251% improvementJehi58%0.42 [0.26-0.68]cases16/529802/11,143Improvement, RR [CI]TreatmentControlZhou (PSM)21%0.79 [0.65-0.94]casesTau​2 = 0.17; I​2 = 83.5%PrEP40%0.60 [0.33-1.11]16/529802/11,14340% improvementAll studies47%0.53 [0.39-0.73]45/869872/11,48247% improvement8 melatonin COVID-19 peer reviewed trialsc19melatonin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.09; I​2 = 58.6%; Z = 3.89Effect extraction pre-specifiedFavors melatoninFavors control 00.250.50.7511.251.51.752+Alizadeh (SB RCT)73%0.27 [0.07-1.05]no recov.2/149/17Improvement, RR [CI]TreatmentControlRamlall87%0.13 [0.08-0.22]death196 (n)752 (n)Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Darban (RCT)6%0.94 [0.84-1.06]ICU10 (n)10 (n)CT​1Hosseini48%0.52 [0.36-0.77]recov. time20 (n)20 (n)Farnoosh (DB RCT)81%0.19 [0.01-3.65]ICU0/242/20Farnoosh (DB RCT)49%0.51 [0.32-0.81]recov. time24 (n)20 (n)Farnoosh (DB RCT)44%0.56 [0.10-3.00]no disch.2/243/20Farnoosh (DB RCT)43%0.57 [0.35-0.92]no disch.24 (n)20 (n)Sánchez-González54%0.46 [0.28-0.71]death24/22453/224Mousavi (RCT)67%0.33 [0.04-3.09]death1/483/48Mousavi (RCT)40%0.60 [0.24-1.52]ICU6/4810/48Jehi58%0.42 [0.26-0.68]cases16/529802/11,143Jehi100%0.00 [0.00-0.05]cases0/18290/2,005Zhou (PSM)21%0.79 [0.65-0.94]casesmelatonin COVID-19 outcomesc19melatonin.com Sep 24, 2021Favors melatoninFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit